[HTML][HTML] Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized …
MHJ Van Oers, M Van Glabbeke… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
MHJ Van Oers, M Van Glabbeke, L Giurgea, R Klasa, RE Marcus, M Wolf, E Kimby…
Journal of clinical oncology, 2010•ncbi.nlm.nih.govPurpose In 2006, we published the results of the European Organisation for Research and
Treatment of Cancer phase III trial EORTC 20981 on the role of rituximab in remission
induction and maintenance treatment of relapsed/resistant follicular lymphoma (FL). At that
time, the median follow-up for the maintenance phase was 33 months. Now, we report the
long-term outcome of maintenance treatment, with a median follow-up of 6 years.
Treatment of Cancer phase III trial EORTC 20981 on the role of rituximab in remission
induction and maintenance treatment of relapsed/resistant follicular lymphoma (FL). At that
time, the median follow-up for the maintenance phase was 33 months. Now, we report the
long-term outcome of maintenance treatment, with a median follow-up of 6 years.
Abstract
Purpose
In 2006, we published the results of the European Organisation for Research and Treatment of Cancer phase III trial EORTC 20981 on the role of rituximab in remission induction and maintenance treatment of relapsed/resistant follicular lymphoma (FL). At that time, the median follow-up for the maintenance phase was 33 months. Now, we report the long-term outcome of maintenance treatment, with a median follow-up of 6 years.
ncbi.nlm.nih.gov